Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6496 to 6510 of 7707 results

  1. Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

    Discontinued [GID-HST10004]

    Highly specialised technologies guidance
    Discontinued

  2. Idebenone for treating Duchenne muscular dystrophy [ID1092]

    Discontinued [GID-TA10310]

    Technology appraisal guidance
    Discontinued

  3. Bevacizumab in combination with chemotherapy for the second line treatment of HER2 negative metastatic breast cancer [ID488]

    Discontinued [GID-TAG432]

    Technology appraisal guidance
    Discontinued

  4. Omburtamab for treating relapsed neuroblastoma [ID1664]

    In development [GID-TA10608] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Avelumab for treating non-small-cell lung cancer after platinum-based chemotherapy [ID1146]

    Discontinued [GID-TA10341]

    Technology appraisal guidance
    Discontinued

  6. Chronic iron overload (in people with thalassaemia) - desferrioxamine, deferiprone and deferasirox [ID350]

    Discontinued [GID-TAG423]

    Technology appraisal guidance
    Discontinued

  7. Personal, social, health and economic education focusing on sex and relationships and alcohol education

    Discontinued [GID-PHG0]

    NICE guideline
    Discontinued

  8. Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]

    In development [GID-TAG499] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]

    Discontinued [GID-TA10164]

    Technology appraisal guidance
    Discontinued

  10. Constipation (opioid induced) - lubiprostone [ID646]

    Discontinued [GID-TAG367]

    Technology appraisal guidance
    Discontinued

  11. Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

    Discontinued [GID-HST10007]

    Highly specialised technologies guidance
    Discontinued

  12. Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]

    Discontinued [GID-TAG507]

    Technology appraisal guidance
    Discontinued

  13. Electrochemotherapy for the treatment of malignant melanoma

    Discontinued [GID-IP1041]

    Interventional procedures guidance
    Discontinued

  14. Pacritinib for treating myelofibrosis [ID880]

    Discontinued [GID-TA10133]

    Technology appraisal guidance
    Discontinued

  15. Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]

    In development [GID-TA10598] Expected publication date: TBC

    Technology appraisal guidance
    In development